Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Shares Issued (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Shares Issued for 17 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 193.1% to -$2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $200000.0, a 99.83% decrease, with the full-year FY2024 number at $5.9 million, down 94.98% from a year prior.
  • Shares Issued was -$2.7 million for Q4 2025 at Myriad Genetics, down from $2.9 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $117.6 million in Q4 2023 to a low of -$3.9 million in Q4 2022.
  • A 5-year average of $19.1 million and a median of $2.7 million in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 8733.33% in 2021, then tumbled 316.67% in 2022.
  • Myriad Genetics' Shares Issued stood at $1.8 million in 2021, then plummeted by 316.67% to -$3.9 million in 2022, then soared by 3115.38% to $117.6 million in 2023, then tumbled by 97.53% to $2.9 million in 2024, then tumbled by 193.1% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Shares Issued are -$2.7 million (Q4 2025), $2.9 million (Q4 2024), and $117.6 million (Q4 2023).